People: ImmunoCellular Therapeutics Ltd (IMUC.A)

IMUC.A on American Stock Exchange

2.56USD
17 May 2013
Price Change (% chg)

$-0.01 (-0.39%)
Prev Close
$2.57
Open
$2.60
Day's High
$2.60
Day's Low
$2.54
Volume
45,956
Avg. Vol
52,377
52-wk High
$3.99
52-wk Low
$1.52

Search Stocks

Summary

Name Age Since Current Position

John Yu

 49 2012 Chairman of the Board, Chief Scientific Officer

Andrew Gengos

 48 2012 President, Chief Executive Officer, Director

David Fractor

 53 2011 Chief Financial Officer, Treasurer

James Bender

 63 2010 Vice President - Product Development & Manufacturing

Rahul Singhvi

 48 2010 Lead Independent Director

Richard Chin

 46 2012 Independent Director

Richard Cowell

 65 2007 Independent Director

Helen Kim

 50 2011 Independent Director

Gary Titus

 53 2012 Independent Director
» Insider Trading

Biographies

Name Description

John Yu

 Dr. John S. Yu, M.D., is Chairman of the Board, Chief Scientific Officer of Immunocellular Therapeutics, Ltd. He has been appointed as Interim President and Chief Executive Officer effective August 14, 2012. Dr. Yu has served as Chief Scientific Officer and a director since November 2006 and Chairman of the Board since January 2007. He is a member of the full-time faculty in the Department of Neurosurgery at Cedars-Sinai Medical Center where he has worked since 1997. An internationally neurosurgeon, Dr. Yu’s clinical focus is on the treatment of malignant and benign brain and spinal tumors. He is also conducting research in immune and gene therapy for brain tumors. He has also done research in the use of neural stem cells as delivery vehicles for brain cancers and neurodegenerative diseases. He was inducted into Castle and Connelly’s America’s Top Doctors in 2005. Dr. Yu has published articles in a number of prestigious journals, including The Lancet, Cancer Research, Cancer Gene Therapy, Human Gene Therapy, Journal of Neuroimmunology, Journal of Neurological Science and Journal of Neurosurgery. Dr. Yu earned his bachelor’s degree in French literature and biological sciences from Stanford University and spent a year at the Sorbonne in Paris studying French literature. He also pursued a fellowship in immunology at the Institut Pasteur in Paris. He earned his medical degree from Harvard Medical School and master’s degree from the Harvard University’s Department of Genetics. He completed his neurosurgical residency at Massachusetts General Hospital in Boston. In addition, he was a Neuroscience Fellow at the National Institutes of Mental Health in the Neuroimmunology Unit at Massachusetts General Hospital from 1988 to 1989 and was a Culpepper Scholar at the Molecular Neurogenetics Unit at that hospital from 1993 to 1995.

Andrew Gengos

 Mr. Andrew Gengos is President, Chief Executive Officer, Director of ImmunoCellular Therapeutics Ltd. Mr. Gengos has served more than 20 years in the life-science industry and was most recently president and CEO at privately-owned Neuraltus Pharmaceuticals. Before that, he spent more than seven years at Amgen Inc. (AMGN) as vice president for strategy and corporate development.

David Fractor

 Mr. David E. Fractor is Chief Financial Officer, Treasurer of ImmunoCellular Therapeutics, Ltd. Since 2003, Mr. Factor has been a consultant providing financial consulting and strategic planning services, including Sarbanes-Oxley compliance consulting services, to a variety of companies in a variety of industries. From 1999 through 2003, Mr. Fractor was the Chief Financial Officer of HemaCare Corporation, a publicly traded corporation which collects, manufactures, tests and distributes blood products to hospitals and provides blood services to patients in hospital settings on an outsourcing basis. Mr. Fractor received his B.S. in Accounting from the University of Southern California in 1982 and is a certified public accountant and a member of AICPA and the California Society of CPA’s.

James Bender

 Dr. James Bender, Ph.D., is Vice President - Product Development and Manufacturing of ImmunoCellular Therapeutics Ltd. Dr. Bender served as Vice President – Clinical Development on a part time basis from September 2008 to February 2010 and has served as Vice President – Product Development and Manufacturing on a full-time basis since February 2010. From 2002 through 2008, Dr. Bender held various positions at IDM Pharma, most recently as director of product development where he led that company’s efforts relating to the clinical development of a cancer vaccine for the treatment of lung cancer. Prior to that, he held various positions at Nexell Therapeutics relating to the development of therapeutic stem cell and cancer vaccine products. Prior to that, Dr. Bender spent 10 years with Baxter Healthcare Corporation, eight years with the University of New Mexico School of Medicine and five years with St. Joseph’s Hospital in Albuquerque, New Mexico. He has over 75 scientific publications, is an inventor of 11 U.S. patents and holds a Ph.D. degree in immunology from the University of New Mexico and an M.P.H. in laboratory management from the University of Michigan.

Rahul Singhvi

 Dr. Rahul Singhvi, Sc.D., is Lead Independent Director of ImmunoCellular Therapeutics, Ltd. He is Managing Partner of MLV Healthcare Partners, a New York based boutique merchant bank, and Axella, LLC, a strategic advisory firm, which positions he has held since 2011. Dr. Singhvi was with Novavax, Inc., a biopharmaceutical company focused on developing novel, potent recombinant vaccines beginning in 2004 and served as President, Chief Executive Officer and a director of Novavax from August 2005 to April 2011. Dr. Singhvi was the Senior Vice President and Chief Operating Officer of Novavax from April 2005 to August 2005 and Vice President – Pharmaceutical Development and Manufacturing Operations from April 2004 to April 2005. For ten years prior to joining Novavax, Dr. Singhvi served in various positions with Merck & Co., Inc., culminating as Director of the Merck Manufacturing Division, where he helped develop several vaccines, including Zostavax ®, the only vaccine on the market to prevent shingles. Dr. Singhvi received his M.S. and Sc.D. degree in Chemical Engineering from the Massachusetts Institute of Technology. He also holds an M.B.A. from the Wharton School.

Richard Chin

 Dr. Richard Chin, M.D., is Independent Director of ImmunoCellular Therapeutics, Ltd. Dr. Chin is a physician with experience in drug development and biologics. He has overseen multiple investigational new drug applications and new drug applications/biologic license applications, and has authored several textbooks on clinical trial medicine. From 2008 until 2011, Dr. Chin served as a director and CEO of OneWorld Health, a nonprofit pharmaceutical company largely funded by the Bill and Melinda Gates Foundation. OneWorld Health is engaged in developing drugs for neglected diseases in impoverished countries. From 2006 to 2008, he was the CEO and President of OXiGENE, and served on its board of directors from 2004 to 2008. From 2004 to 2006, Dr. Chin was at Elan Corporation, where he served, among other roles, as Senior Vice President of Global Development. Dr. Chin also held various clinical and scientific roles for Genentech between 1999 and 2004, including Head of Clinical Research for the Biotherapeutics Unit, overseeing approximately half of the clinical programs at Genentech. Dr. Chin began his career at Procter and Gamble Pharmaceuticals, where he served as Associate Medical Director. He received a B.A. in Biology, magna cum laude, from Harvard University and the equivalent of a J.D. with honors from Oxford University in England under a Rhodes Scholarship. Dr. Chin holds a Medical Degree from Harvard Medical School and is licensed to practice medicine in California. He is currently serves on the Adjunct Faculty of UCSF Medical School, and serves on the Board of Directors of Genmedica, Balance Therapeutics, and Galena Biopharma.

Richard Cowell

 Colonel Retired Richard A. Cowell, USA, is Independent Director of ImmunoCellular Therapeutics Ltd. Colonel Cowell retired in 2011 as a Principal at Booz Allen Hamilton, Inc., where he was involved in advanced concepts, technology experimentation and integration, and establishing new business operations. Prior to joining Booz Allen Hamilton in March 1996, Colonel Cowell served in the United States Army for 25 years. Mr. Cowell serves as a director and Chair of the Audit Committee for Microvision, Inc. He holds a Top Secret security clearance with special accesses based on a special background investigation. Mr. Cowell holds a B.S. degree in accounting from Ohio State University.

Helen Kim

 Ms. Helen S. Kim is Independent Director of ImmunoCellular Therapeutics, Ltd. She has been Chief Business Officer of NGM Pharmaceuticals, Inc., a privately held drug discovery company, since 2009, where she is responsible for all business functions and is active in raising capital. Ms. Kim served as President & Chief Executive Officer of KOSAN Biosciences from 2007 to 2008 where she restructured and repositioned the company prior to the sale of the company to Bristol-Myers Squibb. Ms. Kim served as Chief Program Officer for the Gordon and Betty Moore Foundation from 2003 to 2007. Ms. Kim previously held senior positions with Affymax, Inc., Onyx Pharmaceuticals, Inc., Protein Design Labs, Inc., and Chiron Corporation. She currently serves on the board of directors of Sunesis Pharmaceuticals. Ms. Kim received a M.B.A. in Marketing/Finance from the University of Chicago and a B.S. in Chemical and Biomedical Engineering from Northwestern University.

Gary Titus

 Mr. Gary S. Titus is Independent Director of ImmunoCellular Therapeutics, Ltd. Mr. Titus has held the position of Chief Financial Officer at SciClone since 2008. Prior to SciClone, Mr. Titus served as Senior Vice President of Finance and Chief Financial Officer at Kosan Biosciences, prior to its acquisition by Bristol-Myers Squibb. Prior to that, Mr. Titus was Chief Financial Officer and Vice President at Nuvelo, Inc. Earlier in his career, Mr. Titus held a variety of positions with increasing management responsibilities at other companies, including Metabolex, Inc., Intrabiotics Pharmaceuticals, Inc., and Johnson & Johnson's healthcare division LifeScan, Inc. Mr. Titus earned a Bachelor of Science degree in Accounting from University of South Florida and a Bachelor of Science degree in Finance from University of Florida and is a Certified Public Accountant. He also completed the Global BioExecutive Program at UC Berkeley's Haas School of Business and is a member of several professional organizations.

Basic Compensation

Name Fiscal Year Total

John Yu

 287,225

Andrew Gengos

 824,762

David Fractor

 146,717

James Bender

 366,442

Rahul Singhvi

 --

Richard Chin

 --

Richard Cowell

 --

Helen Kim

 --

Gary Titus

 --
As Of 30 Dec 2012

Options Compensation

Name Options Value

John Yu

 0 0

Andrew Gengos

 0 0

David Fractor

 0 0

James Bender

 0 0

Rahul Singhvi

 0 0

Richard Chin

 0 0

Richard Cowell

 0 0

Helen Kim

 0 0

Gary Titus

 0 0

Insider Trading

Name Shares Traded Price

BENDER JAMES G

 4,900 $3.60

BENDER JAMES G

 600 $3.61

BENDER JAMES G

 1,500 $3.59

BENDER JAMES G

 6,800 $3.92

BENDER JAMES G

 200 $3.94
» Full list on Insider Trading
Search Stocks